• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重新审视“非神经病变型”戈谢病。荷兰一组I型戈谢病患者神经学表现的患病率及文献系统综述

'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature.

作者信息

Biegstraaten M, van Schaik I N, Aerts J M F G, Hollak C E M

机构信息

Department of Neurology, Academic Medical Centre, Amsterdam, The Netherlands.

出版信息

J Inherit Metab Dis. 2008 Jun;31(3):337-49. doi: 10.1007/s10545-008-0832-y. Epub 2008 Apr 4.

DOI:10.1007/s10545-008-0832-y
PMID:18404411
Abstract

Gaucher disease is a lysosomal storage disorder, which is classically divided into three types. Type I Gaucher disease is differentiated from types II and III disease by the absence of nervous system involvement. However, an increasing number of reports has emerged on neurological manifestations in patients with type I Gaucher disease. Whether a strict division in three different phenotypes is still valid has been the subject of debate. The main objective of this study was to provide scientific arguments whether a distinction between type I (non-neuronopathic) and types II and III (neuronopathic) Gaucher disease should be maintained. We investigated retrospectively a large Dutch cohort of type I Gaucher disease patients for the prevalence of neurological manifestations and provide an overview of the literature on this topic. A diagnosis of a neurological disease was made 34 times in 75 patients. Forty-five patients reported at least one neurological symptom during the median follow-up time of 11 years. The literature search revealed 86 studies in which type I Gaucher disease patients or carriers of a glucocerebrosidase mutation were described with a neurological disease or a condition which is known to be associated with neurological disease. In conclusion, the term non-neuronopathic Gaucher disease does not seem to be an appropriate characterization of type I Gaucher disease. However, the neurological signs and symptoms in type I Gaucher disease are of a totally different kind from and, in the majority of cases, of much less severity than the signs and symptoms associated with types II and III disease Therefore, type I disease should be classified as a separate phenotype.

摘要

戈谢病是一种溶酶体贮积症,传统上分为三种类型。I型戈谢病与II型和III型疾病的区别在于无神经系统受累。然而,关于I型戈谢病患者神经学表现的报道越来越多。三种不同表型的严格划分是否仍然有效一直是争论的主题。本研究的主要目的是提供科学依据,以确定是否应维持I型(非神经病变型)与II型和III型(神经病变型)戈谢病之间的区分。我们回顾性调查了一大群荷兰I型戈谢病患者的神经学表现患病率,并对该主题的文献进行了综述。75例患者中有34例被诊断患有神经系统疾病。45例患者在11年的中位随访期内报告了至少一种神经学症状。文献检索发现86项研究,其中描述了I型戈谢病患者或葡萄糖脑苷脂酶突变携带者患有神经系统疾病或已知与神经系统疾病相关的病症。总之,“非神经病变型戈谢病”这一术语似乎并不是I型戈谢病的恰当描述。然而,I型戈谢病的神经体征和症状与II型和III型疾病的体征和症状完全不同,并且在大多数情况下严重程度要低得多。因此,I型疾病应归类为一个单独的表型。

相似文献

1
'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature.重新审视“非神经病变型”戈谢病。荷兰一组I型戈谢病患者神经学表现的患病率及文献系统综述
J Inherit Metab Dis. 2008 Jun;31(3):337-49. doi: 10.1007/s10545-008-0832-y. Epub 2008 Apr 4.
2
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.戈谢病酶替代疗法的临床疗效和成本效益:一项系统评价。
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240.
3
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
4
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
5
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
7
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
8
Type of anaesthesia for acute ischaemic stroke endovascular treatment.急性缺血性脑卒中血管内治疗的麻醉类型。
Cochrane Database Syst Rev. 2022 Jul 20;7(7):CD013690. doi: 10.1002/14651858.CD013690.pub2.
9
Direct composite resin fillings versus amalgam fillings for permanent posterior teeth.直接复合树脂充填与银汞合金充填用于永久性后牙。
Cochrane Database Syst Rev. 2021 Aug 13;8(8):CD005620. doi: 10.1002/14651858.CD005620.pub3.
10
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.欧洲癌症研究与治疗组织(EORTC)癌症贫血患者促红细胞生成蛋白使用指南:2006年更新版
Eur J Cancer. 2007 Jan;43(2):258-70. doi: 10.1016/j.ejca.2006.10.014. Epub 2006 Dec 19.

引用本文的文献

1
A Randomized, Double-Blind, 2-Treatment, 2-Period, Crossover Phase 1 Study to Compare the Pharmacokinetics, Safety and Tolerability of 60 IU/Kg of Abcertin and Cerezyme in Healthy Volunteers Following a Single Intravenous Administration.一项随机、双盲、双治疗、双周期、交叉的1期研究,旨在比较单次静脉给药后,60 IU/Kg阿贝亭和思而赞在健康志愿者体内的药代动力学、安全性和耐受性。
Mol Genet Genomic Med. 2025 Jun;13(6):e70111. doi: 10.1002/mgg3.70111.
2
AAV-mediated GBA1 and GDNF rescue neurological defects in a murine model of neuronopathic Gaucher disease.腺相关病毒介导的葡糖脑苷脂酶1和胶质细胞源性神经营养因子可挽救神经元型戈谢病小鼠模型中的神经缺陷。
Mol Ther Nucleic Acids. 2025 Mar 7;36(2):102506. doi: 10.1016/j.omtn.2025.102506. eCollection 2025 Jun 10.
3

本文引用的文献

1
Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease.来自中国台湾地区散发性帕金森病患者的葡萄糖脑苷脂酶突变
Mol Genet Metab. 2007 Jun;91(2):195-200. doi: 10.1016/j.ymgme.2007.03.004. Epub 2007 Apr 25.
2
Are symptoms of peripheral neuropathy more prevalent in patients with Gaucher disease?戈谢病患者周围神经病变的症状是否更普遍?
Acta Neurol Scand. 2007 Apr;115(4):275-8. doi: 10.1111/j.1600-0404.2006.00774.x.
3
Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier.
Neurological symptoms in adults with Gaucher disease: a systematic review.成人戈谢病的神经系统症状:系统评价。
J Neurol. 2024 Jul;271(7):3897-3907. doi: 10.1007/s00415-024-12439-5. Epub 2024 May 21.
4
The Complexities of Diagnosis with Co-Existing Gaucher Disease and Hemato-Oncology-A Case Report and Review of the Literature.戈谢病与血液肿瘤并存时的诊断复杂性——病例报告及文献综述
J Clin Med. 2023 Aug 25;12(17):5518. doi: 10.3390/jcm12175518.
5
Sphingolipids in neurodegenerative diseases.神经退行性疾病中的鞘脂类
Front Neurosci. 2023 Feb 16;17:1137893. doi: 10.3389/fnins.2023.1137893. eCollection 2023.
6
Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1.患者为中心的戈谢病 1 型实验室诊断指南。
Orphanet J Rare Dis. 2022 Dec 21;17(1):442. doi: 10.1186/s13023-022-02573-6.
7
Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry.2123 例戈谢氏病 1 型患者的癌症风险和丙种球蛋白异常在国际戈谢氏病组织戈谢氏病注册研究中的表现。
Am J Hematol. 2022 Oct;97(10):1337-1347. doi: 10.1002/ajh.26675. Epub 2022 Aug 24.
8
Gaucher disease in North Macedonia: Unexpected prevalence of the N370S GBA1 allele with attenuated disease expression.北马其顿的戈谢病:N370S GBA1等位基因意外的高流行率及疾病表达减弱
Mol Genet Metab Rep. 2022 Jul 8;32:100895. doi: 10.1016/j.ymgmr.2022.100895. eCollection 2022 Sep.
9
Gaucher Disease for Hematologists.戈谢病的血液学特点
Turk J Haematol. 2022 Jun 1;39(2):136-139. doi: 10.4274/tjh.galenos.2021.2021.0683. Epub 2022 Apr 20.
10
In-depth phenotyping for clinical stratification of Gaucher disease.深入表型分析用于戈谢病的临床分层。
Orphanet J Rare Dis. 2021 Oct 14;16(1):431. doi: 10.1186/s13023-021-02034-6.
一名戈谢病患者及其携带者中与帕金森症相关的多巴胺能神经元功能障碍。
J Neurol Sci. 2007 Jan 31;252(2):181-4. doi: 10.1016/j.jns.2006.10.019. Epub 2006 Dec 19.
4
Parkinsonism in type I Gaucher's disease.I型戈谢病中的帕金森综合征
Intern Med. 2006;45(20):1165-7. doi: 10.2169/internalmedicine.45.1790. Epub 2006 Nov 15.
5
Gaucher disease and multiple myeloma.戈谢病和多发性骨髓瘤。
Leuk Lymphoma. 2006 Jul;47(7):1365-8. doi: 10.1080/10428190600565453.
6
Iliopsoas haematoma in Gaucher disease.戈谢病中的髂腰肌血肿。
J Inherit Metab Dis. 2006 Aug;29(4):593. doi: 10.1007/s10545-006-0377-x. Epub 2006 Jul 8.
7
Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism.在帕金森综合征患者中,未发现葡萄糖脑苷脂酶突变与LRRK2 G2019S相关联。
Neurosci Lett. 2006 Aug 14;404(1-2):163-5. doi: 10.1016/j.neulet.2006.05.032. Epub 2006 Jun 15.
8
The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis.887名儿童诊断时非神经病变型戈谢病的临床和人口统计学特征。
Arch Pediatr Adolesc Med. 2006 Jun;160(6):603-8. doi: 10.1001/archpedi.160.6.603.
9
Increased incidence of Parkinson disease among relatives of patients with Gaucher disease.戈谢病患者亲属中帕金森病发病率增加。
Blood Cells Mol Dis. 2006 May-Jun;36(3):426-8. doi: 10.1016/j.bcmd.2006.02.004. Epub 2006 May 2.
10
Parkinsonism in type 1 Gaucher's disease.1型戈谢病中的帕金森综合征
J Neurol Neurosurg Psychiatry. 2006 May;77(5):709-10. doi: 10.1136/jnnp.2005.076240.